LED Device for Non-Invasive Lipolysis

Lipolysis Clinical Trial

Official title:

Feasibility Study of a 950 nm Wavelength LED Device for Non-Invasive Lipolysis of the Flanks

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03171051
• Other study ID #: CS0117
• Status: Terminated
• Phase: N/A
• Start date: June 1, 2017
• Est. completion date: May 16, 2019

Study information

• Verified date: October 2020
• Source: Venus Concept
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to evaluate the ability of a light emitting diode (LED) study device's ability to raise the temperatures on flank tissue to a similar level compared to an approved laser device (SculpSure by Cynosure). Laser treatments have been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.

Description:

This is an open-label, feasibility study comparing the tissue temperature profile of a 950 nm LED device and a 1060 nm diode laser for non-invasive lipolysis of the flanks. The study will enroll up to 10 subjects requesting non-invasive lipolysis of the flanks. Each subject will receive a single treatment with each device on opposite flanks. Tissue temperatures in the treated areas will be recorded at various tissue depths and compared. Subjects will be asked to assess their discomfort and pain of the study treatment using a 10 cm visual analog scale (VAS). In addition, the safety (number of treatment related adverse events) of the LED device will be compared to the reference device at the time of treatment and one week later.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: May 16, 2019
• Est. primary completion date: May 16, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy adult, male or female, = 18 years of age or older with skin types 1-VI.
• Having moderate excess bilateral fatty tissue of the flanks, suitable area for non-invasive lipolysis.
• Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control for at least three months prior to enrolment and throughout the course of the study and have a negative urine pregnancy test at baseline.

Exclusion Criteria:

• Pregnant, expectation of pregnancy, postpartum or nursing (<6 months).
• History of skin disease in the area to be treated over the last 6 months.
• Previous surgical intervention to the treatment area.
• History of skin cancer or pre-cancerous lesions at the treatment areas.
• Having any electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
• History of immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications;
• Uncontrolled systemic diseases such as diabetes.
• Active infections in the treatment area.
• History of dysplastic nevi.
• Significant concurrent skin conditions or any inflammatory skin conditions.
• Active herpes simplex infections (e.g. cold sores), open lacerations or abrasions in the treatment area.
• Chronic or cutaneous viral, fungal, or bacterial diseases.
• Use of Accutane™ (Isotretinoin) within the past six months.
• Keloid or hypertrophic scar formation in the treatment area.
• Tattoos in the treatment area.
• History of auto-immune disorders.
• Erythema abigne, when identified treatments should be discontinued.
• History of photosensitivity disorder that can be exacerbated by laser or intense light.
• Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light.
• History of poor wound healing in the treatment area.
• Sunburns.
• Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a month) and during the course of the evaluation.
• Prior skin treatment with laser or other devices on the same treatment area within the last six months prior to study enrollment or during the course of the study.

Related Conditions & MeSH terms

• Lipolysis

Intervention

Device:
• 950 nm LED Device
Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
• 1050nm Diode Laser Device
FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.

Locations

Country	Name	City	State
United States	Sadick Research Group	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Venus Concept

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Temperature Profile Comparison of the LED Device as Compare to the Reference Device (Diode Laser) at Various Tissue Depths	Immediately (within 2 minutes) after treatment of the area, 3 sterile thermocouple needles of different lengths (9.5-14 mm), will be inserted into the center of each applicator footprint. Temperature readings from each thermocouple needle will be recorded.	At time of treatment
Secondary	Visual Analog Scale (VAS)	Subjects reported level of discomfort and pain after treatment with LED and Laser applicators on a 10 cm horizontal line on which the patient's pain intensity is represented by a point between the extremes of 'no pain at all' (value of 0 cm) and 'worst pain imaginable' (value of 10 cm).	Time of treatment